Thriving in a converging environment: learn how KPMG can help pharmaceutical, medical device and diagnostic companies turn disruption into opportunity.
CMS Announces Model Concepts to Reduce Prescription Drug Costs Model Concepts Provide Glimpse of What May be Ahead for Drug Pricing
Inflation Reduction Act: Part D Benefit Reforms: Impacts on Pharmaceutical Manufacturers, Plans, and Patients Part D Changes Likely to Impact Stakeholder Financial Incentives and Behavior
The Dawn of Precision Medicine in Neurodegenerative Diseases We are on the precipice of Precision Medicine in neurodegenerative diseases (NDDs)
Accelerated Approval Reforms in 2023 Omnibus Accelerated Approval Reforms Will Impact Drug Sponsors and FDA
KPMG 2023 Healthcare and Life Sciences Investment Outlook Our 2023 Healthcare and Life Sciences Investment Outlook finds turbulence, and opportunity, in this post-pandemic marketplace.
Maximizing the potential of your generic portfolio strategy The Inflation Reduction Act may usher in a new era of growth for generics manufacturers.
Shifting from compliance to quality Taking steps toward adopting computer software assurance (CSA) in life sciences
Biopharma Services Industry Update - November 2022 Read more about M&A trends and activity in this sector
Transfer Pricing Considerations in the Age of Precision Medicine Disruption caused by chimeric antigen receptor T-cell (CAR T) therapy, a type of cell and gene therapy, to exploring standard business models in the life sciences industry.
KPMG life sciences technology insights report KPMG reports on the state of life sciences industry digital transformation, automation, artificial intelligence, and machine learning
Inflation Reduction Act impact on biopharma portfolio strategies An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act
Deglobalization: the move to a better world order At a recent WSJ Future of Health forum, Ash Shehata, National Healthcare and Life Sciences lead spoke about Deglobalization.
Inflation Reduction Act: Healthcare provisions and impacts IRA will significantly impact prescription costs and insurance coverage for millions of Americans
Biopharma deal trends outlook for 2022 Deal strategies will focus on risk mitigation, accelerated development, or risk sharing (licensing, partnerships, R&D collaborations).
Psychedelic drugs: A market poised for takeoff With success in clinical trials for a range of mental disorders, psychedelics may soon move to the medical mainstream.
503B outsourcing facilities and pharma manufacturers Why the growth of 503Bs may be an opportunity for traditional pharma
FDA's Accelerated Approval Program: Accelerated Pathway for Reform? Reforms to FDA Accelerated Approval Program could include new confirmatory study requirements.
Pharma leaders collaborate on supply-chain security framework KPMG spearheaded a cross-institutional team of pharma supply-chain leaders to develop a proprietary cybersecurity framework.
2022 Healthcare and Life Sciences Investment Outlook Our 2022 Healthcare and Life Sciences Investment Outlook offers a look into industry innovations with the greatest investor interest.
Managing life sciences channel partners Improving distributor monitoring and compliance in an increasingly complex global life sciences market.
The AI-enabled digital twin for life sciences An Artificial Intelligence (AI) enabled digital twin is a state-of-the-art simulation of a complex real-world system, enhancing predictive AI.
Thriving in an AI World: Life Sciences insights Life sciences companies have turned a corner in the wake of COVID-19 and are now looking toward a smarter, faster future.
ESG reporting – a new opportunity for CAOs How Chief Accounting Officers can lean into the challenge to enhance their strategic roles.
Managing risk and compliance in your SAP S/4HANA journey Life sciences companies face unique governance, risks and compliance challenges when implementing SAP S/4HANA technology.
Getting integration right in biotech acquisitions It takes a delicate balance of control and freedom to pursue innovation.
2021 Healthcare and Life Sciences Investment Outlook Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.
Most Favored Nation Drug Pricing Model final rule On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model.
Generics 2030: Three strategies to curb the downward spiral By 2030, generics manufacturers will need to shift from the status quo and explore one of three avenues for change.
Health Plan Transparency in Coverage Final Rule HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022.
FDA final rule and guidance on importation of prescription drugs FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation.
Executive order on ‘Most-Favored-Nation’ drug pricing An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs.
Executive orders on prescription drug costs Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.
The clinical trial conundrum Failing to resume clinical trials could present as many risks to certain patients as COVID-19.
Re-launching elective procedures An opportunity for medical device companies to shape their future customer base.
KPMG Digital Lighthouse: Powering Life Sciences with advanced analytics The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.
Diagnostics: Ramp-up of testing for COVID-19 & beyond Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach.
Restarting America – Practical Guide for Employers For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.
Part D senior savings model for insulin coverage CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.
2020 healthcare and life sciences investment outlook Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.
Quality 2030 Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator.
Embracing transparency Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.
The race to EU MDR compliance KPMG/RAPS survey illustrates the ground medical device companies still have to cover.
The disruption challenge As new entrants and cross-sector models abound, which direction should healthcare organizations turn?
2018 Health care & life sciences investment outlook Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.